System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alexandros Spyridonidis is an expert in Hematology at General University Hospital of Patras (Greece). As of October 2026, ScienceLeadR ranks Alexandros Spyridonidis in the top 1% of experts worldwide for Cell Transplantation and Anemia, and in the top 1% of experts in Greece for Bone Marrow Transplantation. Alexandros Spyridonidis has authored 211 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 18 of them ongoing. SLR score: 1,220 (community average: 125). How the SLR is computed.

LeadR Profile

Alexandros Spyridonidis General University Hospital of Patras Greece
1 220 ScienceLeadR Reputation 1220

Unlock

Register Login
Network Map

Hematology

Subspecialties: Transplantation - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

University of Patras

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 211

Citations

Citations: 4 794 1st author: 32 Last author: 34 Unique author: 6

Main journals

Bone Marrow Transplant 50
Blood 31
Biol Blood Marrow Transplant 10
Leukemia 9
Transplant Cell Ther 7

Best Journals

Nat Med 2
J Clin Oncol 1
Lancet Haematol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.
PMID 42842316		Blood20260
ELN vs. IPSS-M in MDS/AML: Which Prognostic System Should Guide Clinical Decision-Making?
PMID 42794960 — myelodysplastic syndromes, clinical decision-making, classification, decision making, leukemia, leukemia, myeloid, acute, leukemia, myeloid, therapeutics, artificial intelligence		Cancers (Basel)20260
Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.
PMID 42722785 — registries, cells, incidence, alemtuzumab, bone marrow transplantation, leukemia, transplants, cell transplantation, conditioning, psychological, t-lymphocytes, transplantation		Bone Marrow Transplant20260
Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
PMID 42477157 — cells, blood, whole-body irradiation, bone marrow transplantation, leukemia, drug therapy, transplants, cell transplantation, transplantation, chemotherapy		Bone Marrow Transplant20260
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
PMID 42469396 — blood, bone marrow transplantation, leukemia, transplants, conditioning, psychological, transplantation		Bone Marrow Transplant20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 22
Phase 1/Phase 2 3
Phase 2 3
Phase 1 2

By status:

Recruiting 11
Active not recruiting 8
Completed 8
Suspended 1
Terminated 1
Unknown 1

By type:

Interventional 30

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 2
multicentric5to9 2
multicentricup10 26

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

18 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Randomized Open label Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R miniCHOP) in Older Adults with Untreated Diffuse Large B Cell Lymphoma (ARCHED GLA 2022 1)
2022-501187-18-00 — genes, myc, cells, lymphoma, follicular, hodgkin disease, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, herpesvirus 4, human, rituximab, histiocytes, t-lymphocytes, b-lymphocytes		Phase 3Recruiting2023
A study to investigate the efficacy safety and pharmacokinetics of oral rilzabrutinib compared with placebo in participants 18 years of age and older with warm autoimmune hemolytic anemia
2024-517972-39-00 — safety, anemia, anemia, hemolytic, anemia, hemolytic, autoimmune, pharmacokinetics		Phase 3Recruiting2025
The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle cell disease
2024-518645-17-00 — cells, safety, blood, anemia, sickle cell, lymphatic diseases, aged		Phase 3Recruiting2025
1L LUSPA VS ESA IN NTD LOW RISK MDS PATIENTS
2022-500430-29-00 — epoetin alfa, myelodysplastic syndromes, safety, anemia, therapeutics, erythropoiesis		Phase 3Active not recruiting2023
Phase 3 Study to Evaluate Mezigdomide (CC 92480 BMS 986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma SUCCESSOR 2
2022-500861-29-00 — dexamethasone, multiple myeloma		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS